Cover Image
市場調查報告書

Biotest AG:產品平台分析

Biotest AG - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 251650
出版日期 內容資訊 英文 40 Pages
訂單完成後即時交付
價格
Back to Top
Biotest AG:產品平台分析 Biotest AG - Product Pipeline Review - 2015
出版日期: 2015年05月20日 內容資訊: 英文 40 Pages
簡介

Biotest AG是總公司設置於德國的製藥企業,透過前臨床、臨床開發到銷售的價值鏈來開發、製造、銷售生技藥品。專業領域為臨床免疫學、血液學、集中治療用醫藥品(白蛋白)。經營血漿及服務、其他等三大部門。醫藥品部門則在進行免疫球蛋白、人體血漿製凝血因子及白蛋白等之開發及製造。

本報告提供Biotest AG的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,及最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Biotest AG的基本資料

  • Biotest AG概要
  • 主要資訊
  • 企業資料

Biotest AG:R&D概要

  • 主要的治療範圍

Biotest AG:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

Biotest AG:開發中產品概況

  • 後期階段產品開發中產品
    • 第Ⅲ相的產品/聯合治療模式
  • 臨床階段的開發中產品
    • 第Ⅱ相的產品/聯合治療模式
    • 第Ⅰ相的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

Biotest AG:藥物簡介

  • BT-094
  • hepatitis C virus immune globulin (human)
  • BT-086
  • indatuximab ravtansine
  • tregalizumab
  • fibrinogen concentrate (human)
  • BT-063

Biotest AG:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Biotest AG:最新的開發平台資訊

Biotest AG:開發暫停中的計劃

Biotest AG:企業理念

Biotest AG:總公司和子公司的所在地

  • 總公司
  • 分公司及子公司

Biotest AG:主要的製造設施

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07062CDB

Summary

Global Markets Direct's, 'Biotest AG - Product Pipeline Review - 2015', provides an overview of the Biotest AG's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Biotest AG's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Biotest AG including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Biotest AG's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Biotest AG's pipeline products

Reasons to buy

  • Evaluate Biotest AG's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Biotest AG in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Biotest AG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Biotest AG and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Biotest AG
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Biotest AG and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Biotest AG Snapshot
    • Biotest AG Overview
    • Key Information
    • Key Facts
  • Biotest AG - Research and Development Overview
    • Key Therapeutic Areas
  • Biotest AG - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Biotest AG - Pipeline Products Glance
    • Biotest AG - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Biotest AG - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Biotest AG - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Biotest AG - Drug Profiles
    • BT-094
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • hepatitis C virus immune globulin (human)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BT-086
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • indatuximab ravtansine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tregalizumab
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • fibrinogen concentrate (human)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BT-063
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Biotest AG - Pipeline Analysis
    • Biotest AG - Pipeline Products by Target
    • Biotest AG - Pipeline Products by Route of Administration
    • Biotest AG - Pipeline Products by Molecule Type
    • Biotest AG - Pipeline Products by Mechanism of Action
  • Biotest AG - Recent Pipeline Updates
  • Biotest AG - Dormant Projects
  • Biotest AG - Company Statement
  • Biotest AG - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Biotest AG - Key Manufacturing Facilities
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Biotest AG, Key Information
  • Biotest AG, Key Facts
  • Biotest AG - Pipeline by Indication, 2015
  • Biotest AG - Pipeline by Stage of Development, 2015
  • Biotest AG - Monotherapy Products in Pipeline, 2015
  • Biotest AG - Partnered Products in Pipeline, 2015
  • Biotest AG - Partnered Products/ Combination Treatment Modalities, 2015
  • Biotest AG - Phase III, 2015
  • Biotest AG - Phase II, 2015
  • Biotest AG - Phase I, 2015
  • Biotest AG - Preclinical, 2015
  • Biotest AG - Pipeline by Target, 2015
  • Biotest AG - Pipeline by Route of Administration, 2015
  • Biotest AG - Pipeline by Molecule Type, 2015
  • Biotest AG - Pipeline Products by Mechanism of Action, 2015
  • Biotest AG - Recent Pipeline Updates, 2015
  • Biotest AG - Dormant Developmental Projects,2015
  • Biotest AG, Subsidiaries
  • Biotest AG, Key Manufacturing Facilities

List of Figures

  • Biotest AG - Pipeline by Top 10 Indication, 2015
  • Biotest AG - Pipeline by Stage of Development, 2015
  • Biotest AG - Monotherapy Products in Pipeline, 2015
  • Biotest AG - Pipeline by Top 10 Target, 2015
  • Biotest AG - Pipeline by Top 10 Route of Administration, 2015
  • Biotest AG - Pipeline by Top 10 Molecule Type, 2015
  • Biotest AG - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top